Comparative assessment of siRNA and shRNA off target effects: What is slowing clinical development

Cancer Gene Therapy

Volumn 16, Issue 11, 2009, Pages 807-809

  Rao, D D ^a   Senzer, N ^a,b   Cleary, M A ^c   Nemunaitis, J ^a,b  

^a GRADALIS INC   (United States)

^b Mary Crowley Cancer Research Centers   (United States)

^c ROSETTA INPHARMATICS   (United States)

Author keywords

Cancer therapy; MiRNA; RNAi; ShRNA; SiRNA

Indexed keywords

ARGONAUTE 2 PROTEIN; DNA DIRECTED RNA POLYMERASE III; EXPORTIN 5; MESSENGER RNA; MICRORNA; PROTEIN P53; RNA POLYMERASE II; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

CANCER CELL CULTURE; CANCER GENE THERAPY; CELL STRAIN HCT116; COLON CARCINOMA; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; RNA SEQUENCE; SHORT SURVEY; TOXICOGENETICS;

GENE THERAPY; HUMANS; MICRORNAS; NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 70350130799     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.53     Document Type: Short Survey

References (16)

1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811. (Pubitemid 28099681)
2. Macron D. Breakdown of RNAi-based drugs in the clinic. RNAi News 2008 (online publication at www.rnainews.com October 16, 2008).
3. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-274.
4. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-1113.
5. Nemunaitis J, Senzer N, Khalil I, Shen Y, Kumar P, Tong A et al. Proof concept for clinical justification of network mapping for personalized cancer therapeutics. Cancer Gene Ther 2007; 14: 686-695.
6. Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006; 2: 711-719.
7. Yew NS, Scheule RK. Toxicity of cationic lipid-DNA complexes. Adv Genet 2005; 53: 189-214.
8. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441: 537-541.
9. Grimm D, Kay MA. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest 2007; 117: 3633-3641.
10. Giering JC, Grimm D, Storm TA, Kay MA. Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther 2008; 16: 1630-1636.
11. Fedorov Y, Anderson EM, Birmingham A, Reynolds A, Karpilow J, Robinson K et al. Off-target effects by siRNA can induce toxic phenotype. RNA (New York, NY) 2006; 12: 1188-1196.
12. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L et al. Widespread siRNA 'off-target' transcript silencing mediated by seed region sequence complementarity. RNA (New York, NY) 2006; 12: 1179-1187.
13. Hoerter JA, Walter NG. Chemical modification resolves the asymmetry of siRNA strand degradation in human blood serum. RNA (New York, NY) 2007; 13: 1887-1893.
14. Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev 2009; 61: 746-759.
15. Zeng Y, Cai X, Cullen BR. Use of RNA polymerase II to transcribe artificial microRNAs. Methods Enzymol 2005; 392: 371-380.
16. Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 2005; 37: 1289-1295.